Phaseline

Companies › Mirador Therapeutics

Mirador Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 2; Immunology, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Adecatumumab (MT-201)
Epithelial cell adhesion molecule inhibitor
EPCAMPhase 2Inflammatory Bowel Disease (IBD); Healthy VolunteerNov 2026
MT-501–Phase 2Inflammatory Bowel Disease (IBD)Apr 2027
MT-251–Phase 1Healthy VolunteersMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07776782Adecatumumab (MT-201)Phase 1Healthy VolunteerOtherNov 2026
NCT07219368Adecatumumab (MT-201)Phase 1Healthy VolunteerOtherNov 2026
NCT07423299MT-251Phase 1Healthy VolunteersOtherMar 2027
NCT07113522Adecatumumab (MT-201)Phase 2Inflammatory Bowel Disease (IBD)ImmunologyApr 2027
NCT07113522MT-501Phase 2Inflammatory Bowel Disease (IBD)ImmunologyApr 2027

Targets

EPCAM (1)

Companies with the same targets

Wuhan YZY Biopharma AcadeMab Biomedical BioAtla

Companies built like this

Accro Bioscience (Suzhou) Astria Therapeutics Clarent Biopharma Oruka Therapeutics Shanghai Argo Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.